Blueprint Medicines Corp (BPMC)
106.66
-1.83
(-1.69%)
USD |
NASDAQ |
May 10, 16:00
106.66
0.00 (0.00%)
After-Hours: 20:00
Blueprint Medicines Revenue (TTM): 282.21M for March 31, 2024
Revenue (TTM) Chart
Historical Revenue (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 282.21M |
December 31, 2023 | 249.38M |
September 30, 2023 | 216.20M |
June 30, 2023 | 225.62M |
March 31, 2023 | 204.59M |
December 31, 2022 | 204.04M |
September 30, 2022 | 272.28M |
June 30, 2022 | 230.49M |
March 31, 2022 | 221.24M |
December 31, 2021 | 180.08M |
September 30, 2021 | 107.16M |
June 30, 2021 | 828.10M |
March 31, 2021 | 809.14M |
December 31, 2020 | 793.73M |
September 30, 2020 | 811.16M |
June 30, 2020 | 75.18M |
March 31, 2020 | 71.95M |
Date | Value |
---|---|
December 31, 2019 | 66.51M |
September 30, 2019 | 16.01M |
June 30, 2019 | 7.968M |
March 31, 2019 | 44.30M |
December 31, 2018 | 44.52M |
September 30, 2018 | 45.12M |
June 30, 2018 | 52.09M |
March 31, 2018 | 16.54M |
December 31, 2017 | 21.43M |
September 30, 2017 | 27.49M |
June 30, 2017 | 25.58M |
March 31, 2017 | 26.76M |
December 31, 2016 | 27.77M |
September 30, 2016 | 24.72M |
June 30, 2016 | 21.98M |
March 31, 2016 | 17.60M |
December 31, 2015 | 11.40M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
7.968M
Minimum
Jun 2019
828.10M
Maximum
Jun 2021
293.65M
Average
218.72M
Median
Revenue (TTM) Benchmarks
Apellis Pharmaceuticals Inc | 524.07M |
Alnylam Pharmaceuticals Inc | 2.003B |
Ionis Pharmaceuticals Inc | 776.62M |
Madrigal Pharmaceuticals Inc | -- |
Sarepta Therapeutics Inc | 1.403B |